- Home
- UFCS vs AUTL Comparison
UFCS vs AUTL Comparison
Compare UFCS & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | AUTL |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 596.2M |
| IPO Year | 1995 | 2025 |
Fundamental Metrics
Financial Performance| Metric | UFCS | AUTL |
|---|---|---|
| Price | $56.32 | $1.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $58.50 | $8.73 |
| AVG Volume (30 Days) | 107.0K | ★ 1.5M |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ 87.45 | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $1,386,412,000.00 | $10,120,000.00 |
| Revenue This Year | $15.24 | $98.68 |
| Revenue Next Year | $19.13 | $28.47 |
| P/E Ratio | $22.64 | ★ N/A |
| Revenue Growth | 10.62 | ★ 496.00 |
| 52 Week Low | $29.85 | $1.18 |
| 52 Week High | $56.98 | $2.58 |
Technical Indicators
Market Signals| Indicator | UFCS | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 60.92 | 35.87 |
| Support Level | $51.76 | $1.37 |
| Resistance Level | N/A | $1.73 |
| Average True Range (ATR) | 1.75 | 0.09 |
| MACD | 0.14 | -0.01 |
| Stochastic Oscillator | 85.97 | 6.41 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.